

## AMENDMENTS TO THE CLAIMS

### Listing of Claims

The following listing of claims replaces all previous listings or versions thereof:

1. (Currently amended) A method for targeting an agent to a cancer cell expressing ErbB-2 comprising bringing said cancer cell into contact with a peptide-agent complex, wherein said peptide comprises the sequence KCCYSL (SEQ ID NO:1) and said peptide binds to the extracellular domain of ErbB-2, wherein said agent is a diagnostic agent, a chemotherapeutic, a radiotherapeutic, a toxin or a cytokine.
2. (Original) The method of claim 1, wherein said agent is a diagnostic agent.
3. (Original) The method of claim 2, wherein said diagnostic agent is a radiolabel, a chemilluminescent label, a fluorescent label, a magnetic spin resonance label, or a dye.
4. (Original) The method of claim 3, wherein the diagnostic agent is a radiolabel selected from the group consisting of astatine<sup>211</sup>, <sup>51</sup>chromium, <sup>36</sup>chlorine, <sup>57</sup>cobalt, <sup>58</sup>cobalt, copper<sup>67</sup>, <sup>152</sup>europium, gallium<sup>67</sup>, iodine<sup>123</sup>, iodine<sup>125</sup>, iodine<sup>131</sup>, indium<sup>111</sup>, <sup>59</sup>iron, <sup>32</sup>phosphorus, rhenium<sup>186</sup>, rhenium<sup>188</sup>, <sup>75</sup>selenium, <sup>35</sup>sulphur, technetium<sup>99m</sup>, yttrium<sup>90</sup>, lutetium<sup>177</sup>, samarium<sup>153</sup>, holmium<sup>166</sup>, bismuth<sup>212</sup>, bismuth<sup>213</sup> and actinium<sup>225</sup>.
5. (Currently amended) The method of claim 1, wherein said agent is a therapeutic agent~~chemotherapeutic agent~~.
6. (Currently amended) The method of claim 5, wherein said ~~therapeutic agent is a chemotherapeutic agent, a radiotherapeutic agent, a toxin, a cytokine or a nucleic acid construct.~~
7. (Original) The method of claim 1, wherein said peptide is between 6 and about 100 residues in length.
8. (Original) The method of claim 7, wherein said peptide is between 6 and about 50 residues in length.

9. (Original) The method of claim 8, wherein said peptide is between 6 and about 25 residues in length.
10. (Original) The method of claim 9, wherein said peptide is between about 6 and 15 residues in length.
11. (Original) The method of claim 1, wherein said cell is a cancer cell.
12. (Original) The method of claim 11, wherein said cancer cell is a breast cancer cell.
13. (Original) The method of claim 11, wherein said cancer cell is a prostate cancer cell.
14. (Original) The method of claim 1, wherein said complex further comprises a linking moiety that connects said agent and said peptide.
15. (Original) The method of claim 14, wherein said linking moiety is linked to said peptide through the N-terminal amine, the C-terminal carboxyl group, or a side chain.
16. (Original) The method of claim 1, wherein said cell is located in a subject.
17. (Original) The method of claim 16, wherein said subject is a human.
18. (Original) The method of claim 16, wherein said complex is delivered local or regional to said cell.
19. (Original) The method of claim 16, wherein said complex is delivered systemically.
20. (Original) The method of claim 11, wherein said complex is delivered into vasculature of a tumor comprising said cell.
- 21-76. (Canceled)
77. (New) The method of claim 1, wherein said agent is a toxin.
78. (New) The method of claim 1, wherein said agent is a cytokine.